Marion Teulier1, Alexandre Elabbadi2, Grigorios Gerotziafas3, François Lionnet4, Guillaume Voiriot2, Muriel Fartoukh2. 1. Sorbonne Université, Assistance Publique - Hôpitaux de Paris, Service de médecine intensive réanimation, Hôpital Tenon, Paris, France. marion.teulier@aphp.fr. 2. Sorbonne Université, Assistance Publique - Hôpitaux de Paris, Service de médecine intensive réanimation, Hôpital Tenon, Paris, France. 3. Sorbonne Université, Assistance Publique - Hôpitaux de Paris, Unité d'Explorations Fonctionnelles et Génétiques du Risque Vasculaire, Consultation Thrombose - Oncologie, Hôpital Tenon, Paris, France. 4. Sorbonne Université, Assistance Publique - Hôpitaux de Paris, Service de médecine interne, Hôpital Tenon, Paris, France.
Abstract
BACKGROUND: Sickle-cell anaemia is a widespread genetic disease prevalent worldwide among African and African-American populations. The pathogenesis is most often revealed by pulmonary conditions, including acute thoracic syndrome, which is affecting the life expectancy of these populations. The global spread of CoV2-SARS infection with a respiratory tropism, endothelial damages and procoagulant status endangers the SCD population. However, with only a few case reports, consequences of the Covid-19 pandemic on SCD population remain poorly known. CASE PRESENTATION: We report a case of a 33-year-old man with a history of homozygous SS homozygous sickle cell anemia who consulted on March 24, 2020 for febrile dyspnea 11 days after the onset of symptoms. A nasopharyngeal swab was positive for SARS-CoV-2. His respiratory status worsened rapidly in the emergency room and then in ICU leading to severe ARDS requiring intubation, curarization, and venovenous ECMO. Hematologically, severe hemolysis associated with major thrombocytopenia without documented spinal cord injury was noted. Several transfusion exchanges are performed. The evolution was finally slowly favorable and led to discharge from the intensive care unit and then from the hospital. CONCLUSIONS: This case recalls the importance of an increased prevention policy against COVID-19among the SCD population. In addition, from a therapeutic point of view, it advocates (1) a high preventive anticoagulation from the outset according to the level of D-dimers (2) the use of venovenous ECMO in this particular case, whereas this technique has had rather disappointing results in acute chest syndromes. (3) Unexpectedly, our patient did not develop pulmonary arterial hypertension (PAH) and acute cor pulmonale (ACP), whereas this is a common feature of ARDS during SCD. These last two observations suggest a different pathophysiology of pulmonary disorders in SCD patients in the case of SARS COv2. It could be associated with marked hypoxemia secondary to pulmonary vascular vasodilation.
BACKGROUND: Sickle-cell anaemia is a widespread genetic disease prevalent worldwide among African and African-American populations. The pathogenesis is most often revealed by pulmonary conditions, including acute thoracic syndrome, which is affecting the life expectancy of these populations. The global spread of CoV2-SARSinfection with a respiratory tropism, endothelial damages and procoagulant status endangers the SCD population. However, with only a few case reports, consequences of the Covid-19 pandemic on SCD population remain poorly known. CASE PRESENTATION: We report a case of a 33-year-old man with a history of homozygous SS homozygous sickle cell anemia who consulted on March 24, 2020 for febrile dyspnea 11 days after the onset of symptoms. A nasopharyngeal swab was positive for SARS-CoV-2. His respiratory status worsened rapidly in the emergency room and then in ICU leading to severe ARDS requiring intubation, curarization, and venovenous ECMO. Hematologically, severe hemolysis associated with major thrombocytopenia without documented spinal cord injury was noted. Several transfusion exchanges are performed. The evolution was finally slowly favorable and led to discharge from the intensive care unit and then from the hospital. CONCLUSIONS: This case recalls the importance of an increased prevention policy against COVID-19among the SCD population. In addition, from a therapeutic point of view, it advocates (1) a high preventive anticoagulation from the outset according to the level of D-dimers (2) the use of venovenous ECMO in this particular case, whereas this technique has had rather disappointing results in acute chest syndromes. (3) Unexpectedly, our patient did not develop pulmonary arterial hypertension (PAH) and acute cor pulmonale (ACP), whereas this is a common feature of ARDS during SCD. These last two observations suggest a different pathophysiology of pulmonary disorders in SCDpatients in the case of SARS COv2. It could be associated with marked hypoxemia secondary to pulmonary vascular vasodilation.
Entities:
Keywords:
ARDS; COVID-19; Case report; ECMO; Sickle cell disease
Authors: Florence Boissier; François Bagate; Matthieu Schmidt; Vincent Labbé; Antoine Kimmoun; Muriel Fartoukh; Armand Mekontso Dessap Journal: Crit Care Med Date: 2019-03 Impact factor: 7.598
Authors: John J Strouse; Megan E Reller; David G Bundy; Martha Amoako; Maria Cancio; Rachel N Han; Alexandra Valsamakis; James F Casella Journal: Blood Date: 2010-07-23 Impact factor: 22.113
Authors: Soracha E Ward; Gerard F Curley; Michelle Lavin; Helen Fogarty; Ellie Karampini; Natalie L McEvoy; Jennifer Clarke; Maria Boylan; Razi Alalqam; Amy P Worrall; Claire Kelly; Eoghan de Barra; Siobhan Glavey; Cliona Ni Cheallaigh; Colm Bergin; Ignacio Martin-Loeches; Liam Townsend; Patrick W Mallon; Jamie M O'Sullivan; James S O'Donnell Journal: Br J Haematol Date: 2020-12-16 Impact factor: 6.998
Authors: E P Vichinsky; L D Neumayr; A N Earles; R Williams; E T Lennette; D Dean; B Nickerson; E Orringer; V McKie; R Bellevue; C Daeschner; E A Manci Journal: N Engl J Med Date: 2000-06-22 Impact factor: 91.245
Authors: Frans Beerkens; Mira John; Benjamin Puliafito; Virginia Corbett; Colleen Edwards; Douglas Tremblay Journal: Am J Hematol Date: 2020-04-21 Impact factor: 10.047
Authors: Zsuzsanna Varga; Andreas J Flammer; Peter Steiger; Martina Haberecker; Rea Andermatt; Annelies Zinkernagel; Mandeep R Mehra; Felix Scholkmann; Reto Schüpbach; Frank Ruschitzka; Holger Moch Journal: Lancet Date: 2020-05-19 Impact factor: 79.321
Authors: Erfan Nur; Aafke E Gaartman; Charlotte F J van Tuijn; Man Wai Tang; Bart J Biemond Journal: Am J Hematol Date: 2020-04-21 Impact factor: 10.047
Authors: Wouter S Hoogenboom; Tharun T Alamuri; Daniel M McMahon; Nino Balanchivadze; Vrushali Dabak; William B Mitchell; Kerry B Morrone; Deepa Manwani; Tim Q Duong Journal: Blood Rev Date: 2021-11-20 Impact factor: 10.626